Skip to content

Advertisement

Open Access

Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice

  • Simone de Vasconcelos Generoso1,
  • Núbia Morais Rodrigues4,
  • Luísa Martins Trindade1,
  • Nivea Carolina Paiva2,
  • Valbert Nascimento Cardoso3,
  • Cláudia Martins Carneiro2,
  • Adaliene Versiani de Matos Ferreira1,
  • Ana Maria Caetano Faria4 and
  • Tatiani Uceli Maioli1Email author
Lipids in Health and Disease201514:54

https://doi.org/10.1186/s12944-015-0052-z

Received: 26 January 2015

Accepted: 28 May 2015

Published: 12 June 2015

Abstract

Background

Studies showed the positive effects of omega-3 fatty acid (n-3 FA) for the treatment of inflammatory bowel disease as it alleviated the symptoms and promoted better mucosal integrity. The objective of this study was to determine whether a diet with the addition of n-3 FA helps control the inflammation observed in 5-fluorouracil (5-FU) induced mucositis.

Methods

BALB/c mice were randomly divided into four groups as follows: 1: control (CTL), fed a standard chow diet; 2: CTL + n-3 FA – n-3 FA, fed a diet with n-3; 3: mucositis (MUC), fed a standard chow diet and subjected to mucositis; and 4: MUC+ n-3 FA, fed a diet with n-3 FA and subjected to mucositis. On the 8th day, the animals of the MUC and MUC + n-3 FA groups received an intraperitoneal injection of 300 mg/kg 5-FU for mucositis induction. After 24 h or 72 h, all mice were euthanized and evaluated for intestinal permeability, bacterial translocation, intestinal histology and apoptosis.

Results

Mice that received the diet with n-3 FA and a 5-FU injection showed less weight loss compared to the animals of the MUC group (p < 0.005). Decreased intestinal permeability and bacterial translocation were also observed in animals fed n-3 FA, and these mice underwent mucositis compared to the MUC group (p < 0.005). These data were associated with mucosal integrity and a reduced number of apoptotic cells in the ileum mucosa compared to the mice that received the control diet and 5-FU injection.

Conclusion

Together, these results show that omega-3 fatty acid decreases the mucosal damage caused by 5-FU-induced mucositis.

Keywords

Omega-3 fatty acidMucositisIntestinal damage

Resumo

Introdução

Estudos têm demonstrado efeitos positivos da utilização do ácido graxo ômega-3 (n-3 AG) no tratamento de doenças inflamatórias do intestino, aliviando os sintomas e promovendo melhora da integridade da mucosa. Assim, no presente estudo, foi avaliado o potencial de uma dieta adicionada n-3 AG poderia ajudar a controlar a inflamação observada na mucosite intestinal induzida pelo 5-fluoracil (5-FU).

Métodos

Camundongos BALB/c foram divididos aleatoriamente em quatro grupos: 1. Controle (CTL) - alimentados com ração padrão; 2. CTL + n-3 AG - alimentados com uma dieta adicionada de n-3 AG; 3. Mucosite (MUC) - alimentados com a dieta ração padrão e submetidos à indução da mucosite; 4. MUC + n-3 FA – alimentados com dieta adicionada de n-3 AG e submetidos à indução da mucosite. No oitavo dia, os animais dos grupos MUC e MUC + n-3 AG receberam uma injeção intraperitoneal de 300 mg/kg de 5-FU para a indução da mucosite. Após 24 h ou 72 h, todos os camundongos foram eutanaziados para a avaliação da permeabilidade intestinal, translocação bacteriana, histologia intestinal e ensaio de apoptose.

Resultados

Os animais que receberam a dieta adicionada de n-3 AG e injeção de 5-FU mostraram menor perda de peso comparado com os animais do grupo MUC (p <0,005). Foi observado diminuição da permeabilidade intestinal e translocação bacteriana nos animais alimentados com n-3 AG e submetidos a mucosite. Estes dados foram associadas com melhor integridade da mucosa e uma redução do número de células apoptóticas na mucosa do íleo em comparação com os camundongos que receberam ração controle dieta e injeção com 5-FU.

Conclusão

Estes resultados mostram que o ácido graxo ômega-3 pode diminuir o dano da mucosa causada pela mucosite induzida pelo 5-FU.

Palavras chaves

ácido graxo ômega-3mucositedano intestinal

Background

Polyunsaturated fatty acids (PUFA) are a family of lipids with two or more double bonds [1]. The primary PUFAs are linoleic acid (C18:2n-6) and alpha-linolenic acid (C18:3n-3), and both are essential for metabolism in mammals [1, 2]. PUFAs are important components of cell membranes because of their fluidity [3, 4]. These molecules are substrates for inflammatory and anti-inflammatory eicosanoid production, as exemplified by prostaglandins (PG) and leukotrienes (LTB) [13, 5]. In mammalian cells, omega-6 (n − 6) fatty acid (FA) and omega-3 (n − 3) fatty acid (FA) compete for metabolism by the same enzyme, yielding arachidonic acid or eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), respectively. EPA and DHA can replace arachidonic acid in cell membranes and suppress pro-inflammatory mediator production [4].

Current studies have shown the positive effects of n-3 FA for the treatment of inflammatory bowel disease (IBD), alleviating the symptoms and promoting better mucosal integrity [4, 6, 7]. The most likely mechanism involved is the decreased intestinal production of PG and LTB of odd series [7] precursors of pro-inflammatory cytokines [4, 6]. Additionally, n-3 FA decreased the protein expression of intestinal NFκB p65 related to apoptotic cells [8]. Based on this evidence, supplementation with omega-3 fatty acid may be a good alternative for treating damage caused by mucositis.

Mucositis is the mucosal damage that is secondary to chemotherapy or radiotherapy [9], affecting up to 60 % of patients receiving high-dose chemotherapy and almost 100 % of patients undergoing preconditioning chemotherapy regimens for stem cell transplant [10, 11]. It is characterized by inflammation and/or gastrointestinal tract ulcers, leading to gut mucosal dysfunction, such as diarrhea, weight loss and increased intestinal permeability, which can lead to infections and potentially fatal consequences [12, 13].

This phenomenon occurs because anti-metabolite agents, such as 5-fluorouracil (5-FU), exert their functions in cells that are in the S phase of the cell cycle, inhibiting the synthesis of essential components of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), interrupting cell proliferation [14, 15]. Consequently, there is a promotion of oxidative stress leading to cytotoxic effects on the cells. However, these effects are not restricted to cancer cells. This drug also acts on all proliferative cells, such as mucosal membrane cells; therefore, they are equally sensitive to damage [14].

A previous study from our research group showed that mice that underwent mucositis induced by 5-FU showed a decrease in food consumption, greater weight loss, and increased intestinal permeability and inflammation [16]. Therefore, it is important to investigate the role of n-3 FA in the intestinal damage induced by 5-FU.

Results

Diet with omega-3 fatty acid prevents weight loss, intestinal mucosal damage and bacteria translocation

Figure 1a shows that after both 24 and 72 h of mucositis induction, mice from the MUC group had higher weight loss compared with the control group (p < 0.05). However, mice a fed diet with n-3 FA that underwent mucositis had reduced weight loss (p < 0.05) (Fig. 1a). The difference between the weight on the first day and 72 h after the induction of mucositis showed that mice fed a diet with n-3 FA presented smaller weight loss than the mice of the MUC group (Fig. 1b) (p < 0.05).
Figure 1
Fig. 1

Weight progress. a The mice weights were monitored from the first experimental day to the 11th day. On 8th day mice received an intraperitoneal injection of 5-FU. b The weight loss delta was performed 72 h after mucositis induction subtracting the weight from the first experimental day to the last weight measured. Different letters indicate statistical significance at 11th day (p < 0.05), n = 10

Another consequence of mucositis is intestinal mucosa damage. To determine whether n-3 FA prevents mucosal damage and its initiation, intestinal permeability was evaluated at two time points, 24 h and 72 h. Intestinal permeability was not altered 24 h after mucositis induction (Fig. 2a). However, 72 h after the 5-FU injection (Fig. 2b), the intestinal permeability was higher in the MUC group compared to the CTL group (p < 0.05), whereas, the animals that received n-3 FA and underwent mucositis had decreased intestinal permeability compared to the MUC group mice (p < 0.05).
Figure 2
Fig. 2

The effect of omega-3 fatty acid on intestinal permeability. a Intestinal permeability 24 h after of mucositis induction. b Intestinal permeability 72 h after mucositis induction. Different letters indicate statistical significance, measured by ANOVA (p < 0.05). Data are representative of three different experiments with 5 mice/group each

Bacteria translocation was performed 72 h after mucositis induction (Table 1) and was decreased in mice fed a diet with n-3 FA. The amount of 99mTc-E. coli was lower in the lungs, livers, mesenteric lymph nodes and spleens of the MUC+ n-3 FA mice than in the MUC mice (p < 0.05), indicating that n-3 FA prevented the disruption of the intestinal barrier and, consequently, decreased the BT levels.
Table 1

Bacterial translocation – Tc99m -E. coli

Group/Tissue

CTL

CLT + n-3 FA

MUC

MUC+ n-3 FA

Blood

23.449,19a

21.678,22a

19.376,46a

15.862,66a

Liver

23.078,86a

15.669,89a

125.713,20b

49.781,72a

Spleen

23.840,66a

62.647,74a

189.238,16b

70.816,87a

MLN

56.674,92a

48.248,80a

236.878,69b

156.677,79a

The data are expressed in cpm/g of tissue. Letters a and b = p < 0,05 in the same tissue. MLN: mesenteric lymph node

Histology analyses were used to assess alterations in the ileum mucosa. Sections of small intestine were obtained and analyzed 24 h and 72 h after 5-FU injection. Figure 3a shows that at 24 h after 5-FU injection, no alterations occurred in the ileum mucosa. Although 72 h after mucositis induction, mice from the MUC group showed lesions in the small intestine with cell infiltration in the lamina propria, as well as inflammation in the submucosa and muscular layers. Mice fed a diet with n-3 FA that underwent mucositis showed more preserved ileum mucosa that the MUC group mice and also showed a similar histology compared to the mice that did not received 5-FU (Fig. 3b). The morphometric analyses showed decreased villus and increased crypt heights (Fig. 4d and f) in the MUC group, whereas in the MUC+ n-3FA group, the villus (Fig. 4d) and crypt (Fig. 4e) heights were similar to the CTL and CTL+ n-3FA groups (p < 0.05). Additionally, the mice that received the diet with n-3 FA showed reversed parameters and normal villus/crypt ratios (Fig. 4f). No alterations in the morphometric analyses were observed 24 h after 5-FU injection (Fig. 4a, b and c).
Figure 3
Fig. 3

Ingestion of omega-3 fatty acid inhibited ileum mucosa damage caused by 5-FU. a Normal histological aspects in the ileum mucosa were observed 24 h after 5-FU injection in all groups. b Increased cell infiltration in the lamina propria was observed in the mice that developed mucositis and mucosal architecture disruption was also observed 72 h after 5-FU injection. Bar = 100 μm. The slices were stained with H&E. 100 ×

Figure 4
Fig. 4

Omega-3 fatty acid is able to maintain ileum mucosal architecture in mice with mucositis. a, b and c) Morphometrical analyses of the small intestine slices from the mice treated or not with the n-3-rich diet were performed using ImageJ software 24 h after mucosittis induction. d, e and f Morphomeric analyses after mucositis induction. a and b Villus mean height (μm), (b and e) Lieberkün crypt mean height (μm) and (c and e) ratio between villus and crypt mean heights. Different letters indicate statistical significance calculated by ANOVA (p < 0.05), n = 5

Diet with omega-3 fatty acid can prevent apoptosis induced by 5-FU in the intestinal mucosa

To determine the mechanism by which n-3 FA prevents intestinal damage, mucosal cell apoptosis was measured by immunohistochemistry using TUNEL. Figure 5a shows the labeling of epithelial cells from MUC mice. However, MUC+ n-3FA mice showed results similar to the CTL or CTL+ n-3FA group mice. Apoptotic cell quantification in the ileum mucosa showed a reduced number of apoptotic cells in the MUC+ n-3FA group mucosa compared to the MUC group (Fig. 5b). Therefore, these data suggest that a diet with n-3 FA prevents intestinal cell apoptosis.
Figure 5
Fig. 5

Omega-3 fatty acid prevents apoptosis in the ileum mucosa after 5-FU injection. Ileum fragments were subjected to TUNEL labeling and morphometric analyses. a Few apoptotic cells were labeled in the mucosa from the CTL, CTL + n-3 FA and MUC+ n-3 FA mice. Increased apoptotic cells were observed in the mice that developed mucositis (MUC). Bar = 100 μm. b Villus height and apoptotic cell number ratio. Different letters indicate statistical significance (p < 0.05) that were measured by ANOVA (n = 5/group)

Discussion

In the current study, we demonstrated the positive effect of omega-3 fatty acid in an experimental model of mucositis induced by 5-FU. Our results showed decreased weight loss and intestinal permeability with controlled bacterial translocation and mucosal integrity maintenance in animals fed a diet with n-3 FA 72 h after mucositis induction via the inhibition of apoptosis in ileum mucosal cells.

Analyses of the fatty acid profiles of a diet consisting of fish oil had higher EPA and DHA concentrations compared to the control diet. Although expected, this assessment was important because the n-3 FA used is a commercial product and the quantities expressed on the label may be different. Furthermore, the dietary intake of pre formed EPA and DHA may be more effective than only alpha-linoleic acid consumption [17]. There is convincing evidence that the effects of n-3 FA supplementation are due to the beneficial properties of EPA and DHA [18, 19]. Both molecules have long been proposed to improve health by controlling blood pressure, alleviating symptoms of rheumatoid arthritis and depression, as well as attenuating the progression of Alzheimer’s disease and gut inflammation [16, 1921]. Therefore, we used n-3 to determine whether it controls inflammation in mucositis.

Mucositis is a chemotherapy side effect that is characterized by inflammation from mouth to anus. In humans, it is characterized by weight loss, generalized infection and longer hospitalization time [12, 13]. In mice, the inflammation site depends on the mouse strain and the general effects of the disease [21, 22]. In a previous study with BALB/c mice, gut inflammation was observed mainly in the terminal jejunum and ileum, with significant weight loss [23, 24]. This current study showed high weight loss in animals of the MUC group, 24 h and 72 h post 5-FU injection. However, when mice were fed a diet with n-3 FA and underwent mucositis, they demonstrate less weight loss, at both time points analyzed. These results are consistent with those of Koppelmann et al. [22], who observed less weight loss in rats supplemented with n-3 FA and subjected to methotrexate (MTX)-induced intestinal damage compared to the control group [25]. These results confirm that n-3 diet can prevent weight loss during chemotherapy.

The weight loss observed in animals with mucositis can be explained by the lower absorption of nutrients due to the destruction of the intestinal mucosa architecture with ulcerations and increased intestinal permeability [23, 26]. These alterations allow the luminal contents, including pathogens and toxins, to pass through the intestinal epithelial cell layer, leading to bacterial translocation (BT), which is a cause of several inflammatory reactions observed in the mucositis model [27].

In this study, intestinal permeability was evaluated by measuring blood radioactivity after the oral intake of 99mTc-DTPA. This compound is a disodium complex with a molecular weight of 549 Da and a half-life of 6 h, which satisfies the criteria for a marker that can measure intestinal permeability. Our results showed increased intestinal permeability 72 h after 5-FU injection in animals of the MUC group compared to the animals in the CTL group, but this effect was not observed 24 h after mucositis induction. However, mice that received a diet with n-3 (MUC + n-3) did not have increased intestinal permeability, and this may be the reason for the prevention of weight loss is this group.

Because we did not observe any difference in intestinal permeability at 24 h, we performed the bacteria translocation assay only after 72 h. Greater 99mTc-E. coli uptake was observed in the liver, spleen and mesenteric lymph nodes from animals subjected to mucositis compared to the CTL group. This is related to the increased intestinal permeability [28], which allows the passage of microorganisms into the intestinal lumen, leading to sepsis and death [29]. In this study, mice fed a diet with n-3FA had decreased intestinal permeability and bacterial translocation, even after mucositis induction, compared to mice that did not receive n-3 FA. Bacterial translocation is possible when inflammation and lesions on the small and large intestine are present [28, 30, 31]. One possible explanation for this protective effect of n-3 FA is its regulatory functional capacity to control inflammation, leading to a reduction in mucosal damage [17, 25, 32, 33]. Another explanation for the protective effects of n-3 FA is its action on intestinal cell junctions, such as tight junctions, occludin and ZO-1, which are responsible for regulating paracellular permeability [34, 35]. Beguin and colleagues, [34], using an in vitro intestinal cell translocation model cultivated with omega-3 fatty acid and exposed to inflammatory stimuli, showed that DHA prevented the redistribution of occludin and ZO-1 and that this is induced by inflammatory cytokines. These effects were also observed by Li et al., 2014 and [35].

Weight loss and increased intestinal permeability following 5-FU-induced mucositis are directly associated with intestinal mucosa damage [16, 20, 21]. To determine whether n-3 treatment controls inflammation in the present mucositis model, histological analyses were also performed to determine whether the permeability and BT control occurred via maintenance of the intestinal mucosa architecture. The histological analyses 24 h after 5-FU injection showed no alteration in the ileum mucosa of the small intestine. However 72 h after 5-FU injection, we observed a disruption of the ileum mucosa with increased cellular infiltration in the lamina propria and a decreased villus/crypt ratio. However, mice injected with 5-FU and fed a diet with n-3 showed decreased mucosal inflammation with maintenance of the villus and crypt length, making the MUC + n-3 mice similar to the CTL mice. It was previously described that n-3 FA consumption significantly attenuates intestinal injury [22, 36].

To assess the mechanism by which n-3 FA prevents intestinal damage, we performed an apoptosis assay in the mice ileum mucosa 72 h after the 5-FU injection. It is known that associated mechanisms related to 5-FU-induced mucositis are complex, involving DNA damage, RNA transcription impairment and subsequent apoptosis [37]. Increased apoptosis occurs due to DNA condensation and the activation of caspases with decreased proliferation of villus cells [38, 39]. By contrast, increased EPA or DHA concentrations in the membrane of cells reduce caspase 9 and 3 activation and decrease cytochrome c release, which regulates cellular oxidative stress and controls endothelial cell dysfunction [36, 40]. Using a TUNEL assay, we observed a decreased rate of apoptotic cells in the ileum mucosa of n-3 treated mice that underwent mucositis compared to mice that did not receive n-3 FA. The most likely mechanism is the decrease of caspase activation promoted by n-3 FA in the cells from the ileum mucosa [41, 42]. In the present study, n-3 prevented mucosal apoptosis, and this effect may be related to the mucosal integrity and decreased weight loss in treated mice. However, additional studies should be performed to identify the molecules that are suppressed by n-3 in the apoptosis pathway.

Other nutritional or pharmaceutical agents are also available in a mucositis model. The results changed according to the type or concentration of agent or substance used. Some studies showed that amino acids, such as arginine, glutamine and citrulline, can promote partial mucosal recovery after mucositis induction [4345]. Probiotics and prebiotics have also been extensively studied in mucositis, but with controversial results [16, 4648]. A recent study showed that an herbal preparation with antioxidant properties can decrease the severity of radiation-induced mucositis [49]. Fish oil has been used as an agent to control intestinal inflammation [33, 50] and other inflammatory diseases with no side effects. This may be because it is an essential nutrient [17, 51, 52]. Our data showed that n-3 FA was able to attenuate weight loss, damage of the mucosa, and apoptosis.

Conclusion

Together, our results provide a new preventive treatment for mucositis and confirm the role of omega-3 fatty acid in the prevention of intestinal mucosal inflammation.

Material and methods

Animals, diet treatments, and mucositis induction

Male BALB/c mice between 6 and 8 weeks of age were purchased from Biotério Central of the Instituto de Ciências Biológicas da Universidade Federal de Minas Gerais (UFMG). Mice were housed at room temperature with water and food ad libitum. The UFMG Ethics Committee for Animal Experimentation (CETEA/UFMG) approved this study.

Mice were randomly divided into four groups as follows: 1. Control (CTL), fed standard chow diet; 2. CTL + n-3 FA, fed a diet with n-3 FA; 3. Mucositis (MUC), fed standard chow diet and underwent mucositis; and 4. MUC+ n-3 FA, fed a diet with n-3 FA and underwent mucositis. The CTL and MUC groups received the standard AIN-93G diet ad libitum. The CLT + n-3FA and MUC+ n-3FA groups were fed an experimental diet with added omega-3 fatty acid. Food consumption was calculated as the difference between the amount of offered chow and the residual chow. The individual amount of food ingested was calculated from the average of each cage. The weight of the mice was measured with a semi analytical balance.

The experimental diet was developed based on the AIN93G diet [53]. The AIN93G diet had 7 % lipids (soy oil). For the experimental diet, we used 3.5 % soy oil and 3.5 % fish oil. The total amount of lipids was divided into two parts, 50 % (35 g/kg of chow) soy oil and 50 % (35 g/kg of chow) fish oil. The new formulation is isocaloric compared to AIN93G.

The treatment with these diets was performed for one week prior to mucositis induction, and 24 h or 72 h after 5-FU injection. At the 8th day, mice in the MUC and MUC + n-3 FA groups received an intraperitoneal (IP) injection containing 300 mg/kg 5-FU, whereas the animals of the CTL and CTL + n-3FA groups received a saline IP injection. After 24 h (9th experimental day) or 72 h (11th experimental day), the mice were killed and assessed for intestinal permeability, bacterial translocation, intestinal histology and apoptosis assay.

Diet lipid content analyzes

The fatty acid composition of the diet was determined by gas chromatography (model 6890 N chromatograph, Agilent Technologies) equipped with a fused silica capillary column (SP-2560, 100 m × 0.25 mm × 0.2 mm, Varian Inc.) and a flame ionization detector (FID). Before injection into the chromatograph, the lipid fractions in the feed solution were extracted into hexane-isopropanol as described by Hara and Radin (1978) [54], and the methyl esters were obtained with a basic sodium methoxide catalysis solution [55]. The fatty acids in the samples were identified by comparison to the retention times observed in standard commercial samples (Sigma Diagnostics) based on published articles [56, 57], and the quantification was performed by correcting the peaks to an area of 100 %. According to the lipid content analyses, only the diet made with fish oil had greater amounts of EPA and DHA fatty acids (Table 2).
Table 2

Lipid analysis of the standard diet and dibibet with n-3 FA

 

Total FA

SFA

PUFA

n-3 FA

EPA

DHA

n-6 FA

CTL Chow

97,91 %

15,69 %

55,99 %

4,14 %

0,00 %

0,00 %

50,52 %

n-3FA Chow

78,66 %

8,68 %

54,40 %

24,61 %

15,28 %

7,00 %

26,54 %

The amount of fatty acid is expressed in % of the lipid content. The diet contains 7 % of the lipid

FA: fat acid; SFA: saturated fat acid; PUFA: polyunsaturated fat acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid

Intestinal permeability determination

Intestinal permeability was determined by measuring the radioactivity diffusion in the blood after oral administration of diethylenetriaminepentaacetic acid (DTPA) labeled with 99 m-technetium (99mTc) [58]. After 24 or 72 h of mucositis induction, all mice received 0.1 mL of a DTPA solution labeled with 18.5 mebequerel (MBq) of 99mTc-DTPA by gavage. After four hours, all animals were anesthetized, and 300 μL of blood was collected and placed in the appropriate tubes for radioactivity determination (38). The data are expressed as % dose, using the following equation:
$$ \%\ \mathrm{Dose}=\left(\mathrm{cpm}\ \mathrm{of}\ \mathrm{blood}/\mathrm{cpm}\ \mathrm{of}\ \mathrm{administered}\ \mathrm{dose}\right)\times 100 $$

where cpm represents counts per minute.

E. coli radio labeling and bacterial translocation determination

Bacterial translocation (BT) analysis was performed following a procedure described by Diniz et al. 1999 [59]. An E. coli ATCC10536 sample culture was grown overnight on tryptic casein agar (Difco) that was then transferred to a 10-mL sterile saline solution. The bacterial concentration was adjusted to 31 % of transmittance in a spectrophotometer at 580 nm, which corresponded to approximately 108 CFU/mL. An aliquot of the bacterial suspension (2 mL) was incubated in tubes containing 1 mL of a stannous chloride solution (580 mM, pH 7.0) at 37 °C for 10 min. After incubation, 37.0–55.5 MBq of technetium-99 m (99mTc), which was obtained by elution from a sterile 99Mo/99 m-Tc generator (IPEN/Brazil), was added, and the preparation was incubated at 37 °C for an additional 10 min. The tubes were then centrifuged at 3000 × g for 25 min. This procedure was repeated three times. After the last centrifugation, the radioactivity of the supernatant and precipitate was measured in a dose calibrator (CRC-25R Dose Calibrator, Capintec, Ramsey, USA), and the percentage of 99mTc incorporated into the bacterial cells was determined using the following equation:
$$ =\left(\mathrm{cpm}\ \mathrm{of}\ \mathrm{precipitate}/\mathrm{cpm}\ \mathrm{of}\ \mathrm{precipitate}+\mathrm{cpm}\ \mathrm{of}\ \mathrm{supernatant}\right)\times 100 $$

where cpm represents counts per minute.

After 72 h of mucositis induction, 0.1 mL of a suspension containing 1.8 MBq 99mTc-E. coli was administered by gavage to all of the animals. After four hours, the animals were anesthetized and the blood, mesenteric lymph nodes (MLN), livers and spleens were removed, weighed, and placed into the appropriate tubes for radioactivity determination. The samples were counted in a NaI (Tl) crystal counter (ANSR-Abott, Chicago, USA). The values are expressed as cpm/g or cpm/mL.

Intestinal histology, morphometry, and apoptosis assay

Histology

After 24 or 72 h of mucositis induction, the ileum segments (distal 10 cm) were collected, fixed in methanol with 20 % dimethyl sulfoxide (DMSO) and stained with hematoxylin and eosin for villus height, crypt depth, lamina propria thickness, epithelium thickness, and villus thickness measurements. For each sample, ten intact villi pictures were taken and the parameters were measured.

Morphology

For the morphological analysis, Image J software was used. The villus height was measured from the crypt apex adjacent to the villus apex. The crypt depth was measured from the submucosa to the villus apex. The villi thickness was measured as the largest horizontal villus thickness. The lamina propria thickness was measured as the major horizontal lamina propria thickness. The epithelium thickness was measured as the height of the enterocytes from the edge in contact with the lamina propria to the edge in contact with the intestinal lumen.

Histochemistry

Cell apoptosis in the ileum was detected by a terminal deoxy nucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay using an in situ apoptosis detection kit (FragEL TM DNA Fragmentation Detection Kit, Colorimetric – Klenow Enzyme) according to the manufacturer’s instructions. The results are expressed as the presence or absence of TUNEL positive cells (brown color).

Statistical analysis

The results are expressed as the means ± SD and were analyzed using GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA). Multiple comparison analyses were performed using one-way ANOVA with Tukey post-hoc analysis. Statistical significance was set at P < 0.05.

Declarations

Acknowledgements

We would like to thank the Fundação de Amparo de Ensino à Pesquisa de Minas Gerais (FAPEMIG) and the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) for financial support, and the Pró-Reitoria de Pesquisa - UFMG (PRPq) for providing editing support. We thank Empresa Brasileira de Pesquisa Agropecuária (EMBRAPA) and Patrícia Barros for diet fatty acid composition analyses.

Authors’ Affiliations

(1)
Departamento de Nutrição, Escola de Enfermagem, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
(2)
Núcleo de Pesquisa em Ciências Biológicas, Instituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, Brazil
(3)
Departamento de Análises Clínicas e Toxicológicas, Escola de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
(4)
Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

References

  1. Ratnayake WMN, Galli C. Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper. Ann Nutr Metab. 2009;55:8–43.PubMedView ArticleGoogle Scholar
  2. Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: The anti-inflammatory potential of long-chain omega-3 fatty acids. Nutrition Reviews. 2010;280–289.Google Scholar
  3. Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients. 2010;355–374.Google Scholar
  4. Arisue A, Shimojima N, Tomiya M, Shimizu T, Harada D, Nakayama M, et al. Effect of an omega-3 lipid emulsion in reducing oxidative stress in a rat model of intestinal ischemia − reperfusion injury. Pediatric Surgery International. 2012;913–918.Google Scholar
  5. Burdge GC, Calder PC. Dietary alpha-linolenic acid and health-related outcomes: a metabolic perspective. Nutr Res Rev. 2006;19:26–52.PubMedView ArticleGoogle Scholar
  6. Ibrahim A, Mbodji K, Hassan A, Aziz M, Boukhettala N, Coëffier M, et al. Anti-inflammatory and anti-angiogenic effect of long chain n-3 polyunsaturated fatty acids in intestinal microvascular endothelium. Clin Nutr. 2011;30:678–87.PubMedView ArticleGoogle Scholar
  7. Bento AF, Claudino RF, Dutra RC, Marcon R, Calixto JB. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J Immunol. 2011;187:1957–69.PubMedView ArticleGoogle Scholar
  8. Liu Y, Chen F, Odle J, Lin X, Jacobi SK, Zhu H, et al. Fish Oil Enhances Intestinal Integrity and Inhibits TLR4 and NOD2 Signaling Pathways in Weaned Pigs after LPS Challenge 1–3. 2012.Google Scholar
  9. Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;1453–1461.Google Scholar
  10. Jones JA, Avritscher EBC, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006;14:505–15.PubMedView ArticleGoogle Scholar
  11. Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis SC-E intervention. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol. 2007;5:231–35 ST – Oral mucositis and outcomes of autol.Google Scholar
  12. Keefe DM. Intestinal mucositis: mechanisms and management. Curr Opin Oncol. 2007;19:323–7.PubMedView ArticleGoogle Scholar
  13. Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: Unanswered questions. Oral Oncology. 2003;91–100.Google Scholar
  14. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–8.PubMedView ArticleGoogle Scholar
  15. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277–84.PubMedView ArticleGoogle Scholar
  16. Maioli TU, de Melo SB, Dias MN, Paiva NC, Cardoso VN, Fernandes SO, et al. Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice. J Negat Results Biomed. 2014;13:6.PubMed CentralPubMedView ArticleGoogle Scholar
  17. Yates CM, Calder PC, Ed Rainger G. Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. Pharmacol Ther. 2014;141:272–82.PubMedView ArticleGoogle Scholar
  18. Tanaka S, Saitoh O, Tabata K, Matsuse R, Kojima K, Sugi K, et al. Medium-chain fatty acids stimulate interleukin-8 production in Caco-2 cells with different mechanisms from long-chain fatty acids. J Gastroenterol Hepatol. 2001;16:748–54.PubMedView ArticleGoogle Scholar
  19. Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJA, et al. Eicosapentaenoic acid (EPA) from highly concentrated n − 3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212:252–9.PubMedView ArticleGoogle Scholar
  20. Soares PMG, Mota JMSC, Gomes AS, Oliveira RB, Assreuy AMS, Brito GAC, et al. Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution. Cancer Chemother Pharmacol. 2008;63:91–8.PubMedView ArticleGoogle Scholar
  21. Ferreira TM, Leonel AJ, Melo MA, Santos RRG, Cara DC, Cardoso VN, et al. Oral supplementation of butyrate reduces mucositis and intestinal permeability associated with 5-fluorouracil administration. Lipids. 2012;47:669–78.PubMedView ArticleGoogle Scholar
  22. Koppelmann T, Pollak Y, Mogilner J, Bejar J, Coran AG, Sukhotnik I. Reversal of severe methotrexate-induced intestinal damage using enteral n-3 fatty acids. Br J Nutr. 2013;109:89–98.PubMedView ArticleGoogle Scholar
  23. Thorpe DW, Stringer AM, Gibson RJ. Chemotherapy-induced mucositis: the role of the gastrointestinal microbiome and toll-like receptors. Exp Biol Med (Maywood). 2013;238:1–6.View ArticleGoogle Scholar
  24. Geng L, Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM. Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil. PLoS One. 2011;6.Google Scholar
  25. Koppelmann T, Pollak Y, Mogilner J, Bejar J, Coran AG, Sukhotnik I. Reversal of severe methotrexate-induced intestinal damage using enteral n-3 fatty acids. Br J Nutr. 2012;1–10.Google Scholar
  26. Scully C, Epstein J, Sonis S. Oral mucositis: A challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: Diagnosis and management of mucositis. Head and Neck. 2004;77–84.Google Scholar
  27. Kanarek N, Grivennikov SI, Leshets M, Lasry A, Alkalay I, Horwitz E, et al. Critical role for IL-1β in DNA damage-induced mucositis. Proc Natl Acad Sci U S A. 2014;111:E702–11.PubMed CentralPubMedView ArticleGoogle Scholar
  28. Sánchez de Medina F, Romero-Calvo I, Mascaraque C, Martínez-Augustin O. Intestinal Inflammation and Mucosal Barrier Function. Inflamm Bowel Dis. 2014;20:2394–2404.Google Scholar
  29. Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Cisnal M, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. 2013;19:474–9.PubMedView ArticleGoogle Scholar
  30. Iyama S, Sato T, Tatsumi H, Hashimoto A, Tatekoshi A, Kamihara Y, et al. Efficacy of Enteral Supplementation Enriched with Glutamine, Fiber, and Oligosaccharide on Mucosal Injury following Hematopoietic Stem Cell Transplantation. Case Rep Oncol. 2014;7:692–9.PubMed CentralPubMedView ArticleGoogle Scholar
  31. Touchefeu Y, Montassier E, Nieman K, Gastinne T, Potel G, Bruley des Varannes S, et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - current evidence and potential clinical applications. Aliment Pharmacol Ther. 2014;40:409–21.PubMedGoogle Scholar
  32. Monk JM, Hou TY, Turk HF, McMurray DN, Chapkin RS. n3 PUFAs reduce mouse CD4+ T-cell ex vivo polarization into Th17 cells. J Nutr. 2013;143:1501–8.PubMed CentralPubMedView ArticleGoogle Scholar
  33. Matsunaga H, Hokari R, Kurihara C, Okada Y, Takebayashi K, Okudaira K, et al. Omega-3 polyunsaturated fatty acids ameliorate the severity of ileitis in the senescence accelerated mice (SAM)P1/Yit mice model. Clin Exp Immunol. 2009;158:325–33.PubMed CentralPubMedView ArticleGoogle Scholar
  34. Beguin P, Errachid A, Larondelle Y, Schneider Y-J. Effect of polyunsaturated fatty acids on tight junctions in a model of the human intestinal epithelium under normal and inflammatory conditions. Food Funct. 2013;4:923–31.PubMedView ArticleGoogle Scholar
  35. Li Y, Wang X, Li N, Li J. The study of n-3PUFAs protecting the intestinal barrier in rat HS/R model. Lipids Health Dis. 2014;13:146.PubMed CentralPubMedView ArticleGoogle Scholar
  36. Sun M, Pang L, Ju X, Sun H, Yu J, Zhao H, et al. Attenuating effects of omega-3 fatty acids (Omegaven) on irradiation-induced intestinal injury in mice. Food Chem Toxicol. 2014;64:275–80.PubMedView ArticleGoogle Scholar
  37. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther. 1990;48:381–95.PubMedView ArticleGoogle Scholar
  38. Frank M, Hennenberg EM, Eyking A, Rünzi M, Gerken G, Scott P, et al. TLR signaling modulates side effects of anticancer therapy in the small intestine. J Immunol. 2015;194:1983–95.PubMedView ArticleGoogle Scholar
  39. Zhivotovsky B. Caspases: the enzymes of death. Essays Biochem. 2003;39:25–40.PubMedGoogle Scholar
  40. Taneda S, Honda K, Tomidokoro K, Uto K, Nitta K, Oda H. Eicosapentaenoic acid restores diabetic tubular injury through regulating oxidative stress and mitochondrial apoptosis. Am J Physiol Renal Physiol. 2010;299:F1451–61.PubMedView ArticleGoogle Scholar
  41. Myhrstad MCW, Ulven SM, Günther C-C, Ottestad I, Holden M, Ryeng E, et al. Fish oil supplementation induces expression of genes related to cell cycle, endoplasmic reticulum stress and apoptosis in peripheral blood mononuclear cells: a transcriptomic approach. J Intern Med. 2014;276:498–511.PubMed CentralPubMedView ArticleGoogle Scholar
  42. Barone M, Notarnicola M, Caruso MG, Scavo MP, Viggiani MT, Tutino V, et al. Olive oil and omega-3 polyunsaturated fatty acids suppress intestinal polyp growth by modulating the apoptotic process in ApcMin/+ mice. Carcinogenesis. 2014;35:1613–9.PubMedView ArticleGoogle Scholar
  43. Leocádio PCL, Antunes MM, Teixeira LG, Leonel AJ, Alvarez-Leite JI, Machado DCC, et al. L-arginine pretreatment reduces intestinal mucositis as induced by 5-fu in mice. Nutr Cancer. 2015;67:486–93.PubMedView ArticleGoogle Scholar
  44. Beutheu S, Ouelaa W, Guérin C, Belmonte L, Aziz M, Tennoune N, et al. Glutamine supplementation, but not combined glutamine and arginine supplementation, improves gut barrier function during chemotherapy-induced intestinal mucositis in rats. Clin Nutr. 2014;33:694–701.PubMedView ArticleGoogle Scholar
  45. Antunes MM, Leocadio PCL, Teixeira LG, Leonel AJ, Cara DC, Menezes GB, Generoso S d. V., Cardoso VN, Alvarez-Leite JI, Correia MITD. Pretreatment With L-Citrulline Positively Affects the Mucosal Architecture and Permeability of the Small Intestine in a Murine Mucositis Model. J Parenter Enter Nutr. 2015; jan.8. Epub ahead of print.Google Scholar
  46. Smith CL, Geier MS, Yazbeck R, Torres DM, Butler RN, Howarth GS. Lactobacillus fermentum BR11 and Fructo-Oligosaccharide Partially Reduce Jejunal Inflammation in a Model of Intestinal Mucositis in Rats. Nutr Cancer. 2008;60:757–67.PubMedView ArticleGoogle Scholar
  47. Fang S-B, Shih H-Y, Huang C-H, Li L-T, Chen C-C, Fang H-W. Live and heat-killed Lactobacillus rhamnosus GG upregulate gene expression of pro-inflammatory cytokines in 5-fluorouracil-pretreated Caco-2 cells. Support Care Cancer. 2014;22:1647–54.PubMedView ArticleGoogle Scholar
  48. Flichy-Fernández AJ, Ata-Ali J, Alegre-Domingo T, Candel-Martí E, Ata-Ali F, Palacio JR, Peñarrocha-Diago M. The effect of orally administered probiotic Lactobacillus reuteri-containing tablets in peri-implant mucositis: a double-blind randomized controlled trial. J Periodontal Res. 2015; feb. 25. Epub ahead of print.Google Scholar
  49. El-Ghazaly MA, El-Hazek RM, Khayyal MT. Protective effect of the herbal preparation, STW 5, against intestinal damage induced by gamma radiation in rats. Int J Radiat Biol. 2015;91:150–6.PubMedView ArticleGoogle Scholar
  50. Farrukh A, Mayberry JF. Is there a role for fish oil in inflammatory bowel disease? World J Clin cases. 2014;2:250–2.PubMed CentralPubMedView ArticleGoogle Scholar
  51. Sun R, Wang X, Liu Y, Xia M. Dietary supplementation with fish oil alters the expression levels of proteins governing mitochondrial dynamics and prevents high-fat diet-induced endothelial dysfunction. Br J Nutr. 2014;112:145–53.PubMedView ArticleGoogle Scholar
  52. Swanson D, Block R, Mousa SA. Omega-3 Fatty Acids EPA and DHA: Health Benefits Throughout Life. Adv Nutr An Int Rev J. 2012;3:1–7Google Scholar
  53. Reeves PG, Nielsen FH, Fahey GC. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993;123:1939–51.PubMedGoogle Scholar
  54. Hara A, Radin NS. Lipid extraction of tissues with a low-toxicity solvent. Anal Biochem. 1978;90:420–6.PubMedView ArticleGoogle Scholar
  55. Christie JR, Golinski JV. The spreading of the word: new directions in the historiography of chemistry 1600–1800. Hist Sci. 1982;50:235–66.PubMedView ArticleGoogle Scholar
  56. Destaillats F, Golay PA, Joffre F, de Wispelaere M, Hug B, Giuffrida F, et al. Comparison of available analytical methods to measure trans-octadecenoic acid isomeric profile and content by gas–liquid chromatography in milk fat. J Chromatogr A. 2007;1145:222–8.PubMedView ArticleGoogle Scholar
  57. Izquierdo MS, Robaina L, Juárez-Carrillo E, Oliva V, Hernández-Cruz CM, Afonso JM. Regulation of growth, fatty acid composition and delta 6 desaturase expression by dietary lipids in gilthead seabream larvae (Sparus aurata). Fish Physiol Biochem. 2008;34:117–27.PubMedView ArticleGoogle Scholar
  58. Viana ML, Santos RGC, Generoso SV, Arantes RME, Correia MITD, Cardoso VN. Pretreatment with arginine preserves intestinal barrier integrity and reduces bacterial translocation in mice. Nutrition. 2010;26:218–23.PubMedView ArticleGoogle Scholar
  59. Diniz SOF, Resende BM, Nunan EA, Simal CJR, Cardoso VN. 99mTechnetium labelled Escherichia coli. Appl Radiat Isot. 1999;51:33–6.PubMedView ArticleGoogle Scholar

Copyright

© Generoso et al. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement